Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589551 | 1.00 | CYP19A1 (1.00) | CYP19A1KCNA5KCNH2ALDH1A1GAA | |
| SCHEMBL13234493 | 0.92 | CYP19A1 (0.85) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL2943611 | 0.89 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2ALDH1A1MEN1 | |
| SCHEMBL2948668 | 0.89 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL29963707 | 0.89 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL2953798 | 0.89 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL2949291 | 0.89 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MAPTMEN1 | |
| SCHEMBL5231939 | 0.89 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL734693 | 0.89 | CYP19A1 (0.80) | CYP19A1KCNA5KCNH2ALDH1A1GAA | |
| SCHEMBL13234548 | 0.89 | CYP19A1 (0.79) | CYP19A1KCNA5KCNH2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754041-A4 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMA (US) | 1997-11-19 | — | — | EP | claimed |
| EP-0754041-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS INCORPORATED (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026723-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| CN-114989065-A | Preparation method of indole dimer compound | 中南大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-108997352-A | It can be seen that the method for light-initiated asymmetric syntheses 3- nitrogen oxygroup pyrroles [2,3-b] Benzazole compounds | 云南大学 | 2018-12-14 | — | — | CN | disclosed |
| CN-103980282-A | Method for synthesizing 3-oxo-pyrrol[2,3-b]indole compounds | KUNMING INST BOTANY CN ACAD | 2014-08-13 | — | — | CN | disclosed |
| CN-101675032-B | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands | SUVEN LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-101563321-B | 4- (heterocyclyl) alkyl-N- (arylsulfonyl) indole compounds and their use as 5-HT6Use of ligands | SUVEN LIFE SCIENCES LTD | 2012-05-30 | — | — | CN | disclosed |
| CN-101553467-B | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LTD. (IN) | 2011-12-07 | — | — | CN | disclosed |
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| CN-101563321-A | 4- (heterocyclyl) alkyl-N- (arylsulfonyl) indole compounds and their use as 5-HT6Use of ligands | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-21 | — | — | CN | disclosed |
| CN-101553467-A | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | CN | disclosed |
| US-20060063823-A1 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| EP-0754041-A4 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMA (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0754041-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS INCORPORATED (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5580878-A | TREATING SLEEP DISORDERS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1995026723-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| US-5403851-A | Central nervous system and psychological disorders | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063823-A1 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | PTGIS, MMP15, IL15 | CYP19A1 408/4885KCNA5 1389/4885KCNH2 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.